Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Among patients with provoked VTE and enduring risk factors, low-intensity therapy with apixaban for 12 months resulted in a lower risk of symptomatic recurrent VTE than placebo, with a low risk of major bleeding. (Funded by Bristol-Myers Squibb-Pfizer Alliance; HI-PRO ClinicalTrials.gov number, NCT04168203.).
Authors
- Arvind K. Pandey (ORCID: https://orcid.org/0000-0001-7890-4665)
- John Fanikos (ORCID: https://orcid.org/0000-0002-4218-2637)
- Antoine Bejjani (ORCID: https://orcid.org/0000-0002-8975-7514)
- Sina Rashedi (ORCID: https://orcid.org/0000-0003-0146-5611)
- Samuel Z. Goldhaber
- Behnood Bikdeli (ORCID: https://orcid.org/0000-0003-1428-879X)
- Zhou Lan
- Piotr Sobieszczyk
- Junyang Lou (ORCID: https://orcid.org/0000-0003-2628-1288)
- Gregory Piazza (ORCID: https://orcid.org/0000-0003-1407-5276)
- Umberto Campia (ORCID: https://orcid.org/0000-0002-7894-3565)
- Candrika D. Khairani (ORCID: https://orcid.org/0000-0003-3769-3501)
- Darsiya Krishnathasan (ORCID: https://orcid.org/0000-0002-5405-2733)
- Mariana Pfeferman (ORCID: https://orcid.org/0000-0002-7486-4915)
- Heather Hogan
- Nicole Porio (ORCID: https://orcid.org/0009-0007-2786-9821)
- Lisa Rosenbaum
- Ruth Morrison
- Marie Gerhard-Herman
Institutions
- Brigham and Women's Hospital (US)
- Yale New Haven Hospital (US)
- University of Pittsburgh (US)
- Hadassah Medical Center (IL)
- Thrombolysis in Myocardial Infarction Study Group (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1056/nejmoa2509426
- Citations
- 20
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 37.40
Funders
- Bristol-Myers Squibb Foundation